跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Coronavirus disease-19 vaccine
首页
药物
Coronavirus disease-19 vaccine
Coronavirus disease-19 vaccine
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE
EP 4248983 A3
申请人: AKSTON BIOSCIENCES CORP
优先权: 2020
CN
EP
US
5 件公开
NOVEL SALMONELLA-BASED CORONAVIRUS VACCINE
EP 4126022 A1
申请人: NEC ONCOIMMUNITY AS
优先权: 2020
CN
EP
US
WO
4 件公开
Coronavirus disease (COVID-19) vaccine
US 11478543 B1
申请人: UNIV JEFFERSON
优先权: 2020
CN
US
4 件公开
NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE
EP 4676530 A2
申请人: VAKSTON INC
优先权: 2023
CN
EP
WO
3 件公开
VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2
EP 4727580 A1
申请人: SEQIRUS INC
优先权: 2023
CN
EP
WO
3 件公开
NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF
US 20250108106 A1
申请人: FULGENT GENETICS INC
优先权: 2022
CN
US
2 件公开
A method of preventing and treating disease with transformed microbes
US 20260216253 A1
申请人: EKEMA GEORGE MBELLA
优先权: 2022
US
WO
2 件公开
AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS
EP 4669349 A2
申请人: INST IMMUNOLOGII I TERAPII DOSWIADCZALNEJ IM LUDWIKA HIRSZFELDA POLSKIEJ AKADEMII NAUK
优先权: 2023
EP
WO
2 件公开
Attenuated poxvirus vector-based vaccines for protection against COVID-19
CN 115605225 A
申请人: SYMENDIS LTD
优先权: 2020
CN
Bat-derived coronavirus vaccine for preventing COVID-19
CN 111437384 A
申请人: SICHUAN CHENGYU BIOLOGICAL PRODUCTS CO LTD
优先权: 2020
CN
第 1 / 3 页
上一页
下一页
药物
反馈